Greenwich Lifesciences Stock Performance
| GLSI Stock | USD 26.85 1.12 4.35% |
Greenwich Lifesciences holds a performance score of 21 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 2.46, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Greenwich Lifesciences will likely underperform. Use Greenwich Lifesciences value at risk, and the relationship between the jensen alpha and skewness , to analyze future returns on Greenwich Lifesciences.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Greenwich Lifesciences are ranked lower than 21 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Greenwich Lifesciences demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Greenwich | Build AI portfolio with Greenwich Stock |
Greenwich Lifesciences Relative Risk vs. Return Landscape
If you would invest 823.00 in Greenwich Lifesciences on November 16, 2025 and sell it today you would earn a total of 1,862 from holding Greenwich Lifesciences or generate 226.25% return on investment over 90 days. Greenwich Lifesciences is currently generating 2.3154% in daily expected returns and assumes 8.6666% risk (volatility on return distribution) over the 90 days horizon. In different words, 77% of stocks are less volatile than Greenwich, and 54% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Greenwich Lifesciences Target Price Odds to finish over Current Price
The tendency of Greenwich Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 26.85 | 90 days | 26.85 | about 17.83 |
Based on a normal probability distribution, the odds of Greenwich Lifesciences to move above the current price in 90 days from now is about 17.83 (This Greenwich Lifesciences probability density function shows the probability of Greenwich Stock to fall within a particular range of prices over 90 days) .
Greenwich Lifesciences Price Density |
| Price |
Predictive Modules for Greenwich Lifesciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Greenwich Lifesciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Greenwich Lifesciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Greenwich Lifesciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Greenwich Lifesciences is not an exception. The market had few large corrections towards the Greenwich Lifesciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Greenwich Lifesciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Greenwich Lifesciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 2.16 | |
β | Beta against Dow Jones | 2.46 | |
σ | Overall volatility | 8.59 | |
Ir | Information ratio | 0.26 |
Greenwich Lifesciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Greenwich Lifesciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Greenwich Lifesciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Greenwich Lifesciences is way too risky over 90 days horizon | |
| Greenwich Lifesciences appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (15.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Greenwich Lifesciences currently holds about 15.64 M in cash with (7.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22. | |
| Greenwich Lifesciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 51.0% of the company shares are held by company insiders |
Greenwich Lifesciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Greenwich Stock often depends not only on the future outlook of the current and potential Greenwich Lifesciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Greenwich Lifesciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 13 M | |
| Cash And Short Term Investments | 4.1 M |
Greenwich Lifesciences Fundamentals Growth
Greenwich Stock prices reflect investors' perceptions of the future prospects and financial health of Greenwich Lifesciences, and Greenwich Lifesciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Greenwich Stock performance.
| Return On Equity | -5.43 | ||||
| Return On Asset | -2.54 | ||||
| Current Valuation | 352.25 M | ||||
| Shares Outstanding | 13.85 M | ||||
| Price To Book | 175.72 X | ||||
| EBITDA | (15.79 M) | ||||
| Cash And Equivalents | 15.64 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 1.56 M | ||||
| Book Value Per Share | 0.16 X | ||||
| Cash Flow From Operations | (7.27 M) | ||||
| Earnings Per Share | (1.46) X | ||||
| Total Asset | 4.09 M | ||||
| Retained Earnings | (66.15 M) | ||||
About Greenwich Lifesciences Performance
By evaluating Greenwich Lifesciences' fundamental ratios, stakeholders can gain valuable insights into Greenwich Lifesciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Greenwich Lifesciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Greenwich Lifesciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. Greenwich Lifesciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.Things to note about Greenwich Lifesciences performance evaluation
Checking the ongoing alerts about Greenwich Lifesciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Greenwich Lifesciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Greenwich Lifesciences is way too risky over 90 days horizon | |
| Greenwich Lifesciences appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (15.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Greenwich Lifesciences currently holds about 15.64 M in cash with (7.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22. | |
| Greenwich Lifesciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 51.0% of the company shares are held by company insiders |
- Analyzing Greenwich Lifesciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Greenwich Lifesciences' stock is overvalued or undervalued compared to its peers.
- Examining Greenwich Lifesciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Greenwich Lifesciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Greenwich Lifesciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Greenwich Lifesciences' stock. These opinions can provide insight into Greenwich Lifesciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Greenwich Stock analysis
When running Greenwich Lifesciences' price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |